TRIUMPH-2 To Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants with Type 2 Diabetes Mellitus who have Obesity or Overweight and Sleep Apnoea: A Randomized, Double-Blind, Placebo-Controlled Trial.

You are eligible if you are:

  • >18 years old and:
  • are overweight (BMI>27kg/m2)
  • have type 2 diabetes
  • have a history of at least one dietary effort to lose body weight
  • previously diagnosed with obstructive sleep apnoea

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared with Placebo in Adult Participants with Obesity or Overweight and Type 2 Diabetes

You are eligible if you are >18 years old and:

  • are overweight (BMI>27kg/m2)
  • have type 2 diabetes
  • have a history of at least one dietary effort to lose body weight

ATTAIN-2

A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants with Severe Obesity and Established Cardiovascular Disease

You are eligible if you are >18 years old and:

  • are overweight (BMI>35kg/m2)
  • have established cardiovascular disease and can answer yes to one of the following:
    • prior myocardial infarction
    • prior stroke
    • peripheral arterial vascularization
    • amputation due to vascular disease
    • symptomatic vascular disease.
  • have a history of at least one dietary effort to lose body weight

TRIMPUH-3 

 The Metformin Aneurysm Trial (MAT)

An investigator initiated and conducted, multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial to determine the effect of metformin on abdominal aortic aneurysm (AAA) associated events, including AAA repair and AAA mortality (due to aneurysm rupture).

You may be eligible if you:

  • have an abdominal aortic aneurysm
  • are aged between 18 – 79 years old
  • are not taking metformin

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity

You are eligible if you:

  • are overweight (BMI>27kg/m2)
  • do not have diabetes
  • have established cardiovascular disease (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) OR can answer yes to two of the following:
    • are a current smoker
    • have high cholesterol
    • have high blood pressure
    • have kidney disease
    • have prediabetes